Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma.
OBJECTIVE
To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib.


METHODS
Case report.


RESULTS
A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma. The patient was successfully treated with sub-Tenon triamcinolone injections along with cessation of the medication.


CONCLUSIONS
Panuveitis is a potential adverse effect of vemurafenib. Good communication with oncology is necessary, in case the medication needs to be discontinued.
Department of Ophthalmology, Kresge Eye Institute/Wayne State University School of Medicine, Detroit, Michigan - USA.
Steven A
SA
Agemy
Ankur N
AN
Mehta
Sophia I
SI
Pachydaki
Asheesh
A
Tewari
D000328:Adult; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008269:Macular Edema / Q000139:chemically induced / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009367:Neoplasm Staging; D015864:Panuveitis / Q000139:chemically induced* / Q000188:drug therapy; D000090063:Proto-Oncogene Mas; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012008:Recurrence; D012878:Skin Neoplasms; D013449:Sulfonamides / Q000009:adverse effects*; D058475:Tenon Capsule / Q000187:drug effects; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D000077484:Vemurafenib; D000096142:Cutaneous Malignant Melanoma
D007211:Indoles; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D013449:Sulfonamides; D000077484:Vemurafenib; D048493:Proto-Oncogene Proteins B-raf; D014222:Triamcinolone Acetonide